Home › Endometrial Cancer › Illinois › Cicero
Endometrial Cancer clinical trials in Cicero, IL
4 studies for Endometrial Cancer are looking for participants at sites in and around Cicero (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- Rush MD Anderson Cancer Center at Rush Oak Park, Oak Park · 3 mi away
- Northwestern Medicine Oak Brook, Oak Brook · 9 mi away
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Loyola University Medical Center, Maywood · 5 mi away
- Advocate Christ Medical Center, Oak Lawn · 9 mi away
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Hope and Healing Cancer Services, Hinsdale · 10 mi away
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
RecruitingPhase 2/3
- Dr. Sudarshan K. Sharma, Ltd., Hinsdale · 10 mi away
Endometrial Cancer trials in other cities
- Houston, TX69 studies
- New York City, NY53 studies
- Boston, MA50 studies
- Arlington, VA39 studies
- Nashville, TN37 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- San Antonio, TX27 studies
- Columbus, OH26 studies
- Chicago, IL26 studies
- Queens, NY26 studies
Other studies in Cicero
- Non-Small Cell Lung Cancer24 studies
- Lung Cancer17 studies
- Prostate Cancer14 studies
- Cancer (all types)13 studies
- Breast Cancer11 studies
- Acute Myeloid Leukemia11 studies
- Colorectal Cancer9 studies
- Bladder Cancer8 studies
- Metastatic Cancer7 studies
- Cardiovascular Disease7 studies
- Melanoma7 studies
- Pancreatic Cancer6 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.